Cytodyn Inc (CYDY)

[Amatuer17]

Good point - when a BP wants to biy the company for the drug - they evaluate the drug efficacy and potential revenue it can generate.

If there is not much potential to sell pro-140 as adjunct - BP will just wait for Mono trial to get over and show efficacy. The mc of the company is so small that a doubling of mc won't matter to BP rather than taking risk by buying the co early.

So CYDY will have to come with strong marketing pitch for selling the drug which will lead to selling the co
Else co will have keep on raise money till end of trial diluting further and thus getting much lower valuation